Skip secondary menu

Funding News - Preclinical Therapeutics Development for NeuroAIDS Encouraged

Archive folder iconHistorical Data

  • The information on this page is for historical and research purposes only.
  • For the most current NINDS funding announcements, please see the NINDS list of Active Funding Initiatives or Follow Us on Twitter for the latest funding news.

The National Institute of Neurological Disorders and Stroke (NINDS) encourages grant applications proposing novel models of HIV-related central nervous system (CNS) and peripheral nervous system (PNS) damage that can be used to screen for compounds showing promise as treatments in patients. This announcement is made together with 2 other components of the National Institutes of Health (NIH) and is supported by 2 funding mechanisms: R21 and R03.

Since the availability of the first antiretroviral therapy zidovudine in 1987 and sequential discoveries of other antiretroviral agents there has been a dramatic decrease in mortality and morbidity among the HIV/AIDS population. However, despite these important advances, the prevalence of HIV-associated mental and neurological disorders is reported to be increasing, in part because of the prolonged lifespan of infected patients. The purpose of this announcement is to encourage the development and/or validation of new in vitro and in vivo models of HIV or HAART-related neurotoxicity that show promise for use in the screening of novel CNS- and PNS-targeted therapeutic compounds.

For more information, potential applicants should contact Dr. Michael Nunn, Program Director, Neural Environment Cluster, NINDS; telephone: 301-496-1431; e-mail: mn52e@nih.gov. For a more detailed description of this announcement, visit http://grants.nih.gov/grants/guide/pa-files/PA-06-528.html (R21) or http://grants.nih.gov/grants/guide/pa-files/PA-06-529.html (R03).